10-Q: Surgery Partners Reports Mixed Q3 Results Amidst Revenue Growth and Increased Expenses

Surgery Partners saw a revenue increase of 14.3% in the third quarter of 2024, but also experienced a net loss attributable to Surgery Partners, Inc. of $31.7 million.

Summary

• Surgery Partners reported a 14.3% increase in total revenue for the third quarter of 2024, reaching $770.4 million, compared to $674.1 million in the same period of 2023.
• The revenue growth was driven by a 4.2% increase in days adjusted same-facility revenues, which included a 3.7% rise in same-facility cases and a 0.5% increase in revenue per case.
• Adjusted EBITDA for the third quarter of 2024 increased by 21.9% to $128.6 million, up from $105.5 million in the third quarter of 2023.
• However, the company reported a net loss attributable to Surgery Partners, Inc. of $31.7 million for the third quarter of 2024, compared to a loss of $4.9 million in the same period of 2023.
• For the nine months ended September 30, 2024, total revenue was $2,249.9 million, an 11.6% increase compared to $2,007.9 million for the same period in 2023.
• The company's net loss attributable to Surgery Partners, Inc. for the nine months ended September 30, 2024, was $59.6 million, compared to a loss of $10.9 million for the same period in 2023.
• The company acquired a controlling interest in several physician practices for $26.6 million during the third quarter of 2024.
• As of September 30, 2024, Surgery Partners had $221.8 million in cash and cash equivalents and $595.8 million of borrowing capacity under its revolving credit facility.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with strong revenue growth and EBITDA improvement offset by a net loss and increased expenses. The company's future outlook is cautiously optimistic, but there are significant risks and challenges to consider.

Positives

• Surgery Partners experienced a significant increase in revenue, driven by both same-facility growth and acquisitions.
• Adjusted EBITDA showed a strong increase, indicating improved operational efficiency.
• The company has a substantial amount of cash and borrowing capacity available.
• Same-facility case volumes and revenue per case both increased.

Negatives

• The company reported a net loss attributable to Surgery Partners, Inc. for both the third quarter and the nine-month period.
• Transaction and integration costs increased significantly in both the three and nine month periods.
• Depreciation and amortization expenses increased significantly in both the three and nine month periods.
• The company's income tax expense increased significantly for the nine month period.

Risks

• The company is subject to risks related to changes in interest rates, inflation, and supply chain issues.
• There is a risk of reduced payments from government health care programs and private insurance payors.
• The company faces competition for physicians, nurses, strategic relationships, acquisitions, and managed care contracts.
• The company's ability to collect outstanding receivables could be negatively affected by economic conditions.
• The company is subject to legal and regulatory proceedings that could have a material adverse effect on its business.
• Cybersecurity attacks or intrusions could impact the company's operations.

Future Outlook

The company continues to focus on improving same-facility performance, selectively acquiring established facilities, developing new facilities, and other portfolio management initiatives. The company believes that cash flows from operations, available cash, available capacity on its Revolver and continued anticipated access to capital markets, will be adequate to meet its short-term and long-term liquidity needs.

Management Comments

• Management uses Adjusted EBITDA as a key measure to assess operating performance, make business decisions, and allocate resources.
• Management believes that the company's current level of operations, cash flows, and access to capital will be adequate to meet liquidity needs.

Industry Context

The healthcare industry is facing challenges related to reimbursement rates, regulatory changes, and competition. Surgery Partners' results reflect these industry-wide trends, with revenue growth offset by increased expenses and a net loss. The company's focus on acquisitions and same-facility growth is a common strategy in the industry to achieve scale and improve profitability.

Comparison to Industry Standards

• Surgery Partners' revenue growth of 14.3% in Q3 2024 is a strong result compared to some of its peers in the ambulatory surgery center sector, such as AmSurg and United Surgical Partners International, which have reported more modest growth rates in recent quarters.
• However, the net loss reported by Surgery Partners contrasts with the profitability of some of its larger competitors, indicating potential challenges in cost management and operational efficiency.
• The company's Adjusted EBITDA growth of 21.9% is a positive sign, but it is important to compare this metric to industry benchmarks to assess its relative performance.
• The company's debt levels are significant, and it is important to compare its leverage ratios to industry averages to assess its financial risk.
• The company's acquisition strategy is consistent with industry trends, but the success of these acquisitions will depend on effective integration and cost synergies.

Stakeholder Impact

• Shareholders may be concerned about the net loss, but encouraged by the revenue growth and EBITDA improvement.
• Employees may be affected by the company's cost management initiatives.
• Customers (patients) may experience changes in service offerings as the company integrates acquisitions.
• Suppliers may see increased demand as the company expands its operations.
• Creditors may be monitoring the company's debt levels and ability to repay its obligations.

Next Steps

• The company will continue to focus on improving same-facility performance.
• The company will continue to selectively acquire established facilities.
• The company will continue to develop new facilities.
• The company will continue to pursue other portfolio management initiatives.

Key Dates

Keywords

Surgical Facilities, Ambulatory Surgery Centers, Healthcare, Revenue Growth, EBITDA, Acquisitions, Financial Results, Net Loss, Physician Practices, Debt